Details werden geladen...
Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results | The Manila Times
Robust response in highest dose cohort after 36 weeks following a single treatment of EP-104GI
Ähnliche Seiten
Ferroglobe Reports First Quarter 2026 Financial Results | The Manila Times
https://www.manilatimes.net/2026/05/06/tmt-newswire/globenewswire/ferroglobe-reports-first-quarter-2026-financial-results/2336637Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update | The Manila Times
https://www.manilatimes.net/2026/05/13/tmt-newswire/globenewswire/atea-pharmaceuticals-reports-first-quarter-2026-financial-results-and-provides-business-update/2342286Radware Reports First Quarter 2026 Financial Results | The Manila Times
https://www.manilatimes.net/2026/05/07/tmt-newswire/globenewswire/radware-reports-first-quarter-2026-financial-results/2338122illumin Reports First Quarter 2026 Financial Results | The Manila Times
https://www.manilatimes.net/2026/05/08/tmt-newswire/globenewswire/illumin-reports-first-quarter-2026-financial-results/2339400Perimeter Solutions Reports First Quarter 2026 Financial Results | The Manila Times
https://www.manilatimes.net/2026/05/06/tmt-newswire/globenewswire/perimeter-solutions-reports-first-quarter-2026-financial-results/2336901